AVTX - CIK 0001534120
The table below shows Avalo Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$17.69M | -$9.46M | -$6.20M | -$10.05M | -$16.07M | -$18.32M |
| Capital expenditure | - | - | - | - | $0.00 | $21.00K |
| Investing cash flow | $25.50M | $0.00 | $356.00K | -$133.00K | $0.00 | -$21.00K |
| Dividends paid | - | - | - | - | - |
Avalo Therapeutics, Inc. reported operating cash flow of -$51.46M for fiscal year 2025. That is down 4.9% from -$49.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.57M (FY 2016) to -$51.46M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.40M | $0.00 | $108.61M | $13.75M | $0.00 | $37.83M |